Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease ProgramsCALGARY, Alberta, April 28, 2025 (GLOBE ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

An extensive library of compounds was synthesized and evaluated in several in vitro and in vivo assays designed to measure anti-tubulin activity and inhibition of xanthine oxidase. These results led ...

Allopurinol is a xanthine oxidase inhibitor, recommended for treating the increased uric acid levels caused by cancer drugs.

The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of ...